These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16866664)

  • 1. Imatinib-induced cytogenetic remission in chronic eosinophilic leukaemia.
    Willson A; Cannell P; Joske D; Augustson B
    Intern Med J; 2006 Aug; 36(8):537-8. PubMed ID: 16866664
    [No Abstract]   [Full Text] [Related]  

  • 2. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
    Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C
    Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
    [No Abstract]   [Full Text] [Related]  

  • 3. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
    Ghanima W; Kahrs J; Dahl TG; Tjonnfjord GE
    Eur J Haematol; 2004 Jun; 72(6):441-3. PubMed ID: 15128424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
    Chen F; Li L; Ma D; Yan S; Sun J; Zhang M; Ji C; Hou M
    Leuk Res; 2010 Feb; 34(2):e75-7. PubMed ID: 19773083
    [No Abstract]   [Full Text] [Related]  

  • 5. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
    Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
    Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib.
    Gambacorti-Passerini C
    Haematologica; 2005 Apr; 90(4):434. PubMed ID: 15820927
    [No Abstract]   [Full Text] [Related]  

  • 8. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic variables in patients with chronic myeloid leukemia treated with imatinib.
    Gambacorti-Passerini C
    Haematologica; 2006 Feb; 91(2):145a. PubMed ID: 16461289
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 14. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 15. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
    Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
    Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
    Oku E; Imamura R; Nagata S; Takata Y; Seki R; Otsubo K; Hashiguchi M; Osaki K; Yakushiji K; Yoshimoto K; Ogata H; Sata M; Okamura T
    Acta Haematol; 2007; 117(4):191-6. PubMed ID: 17170522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
    Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
    Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
    Pavlu J; Andreasson C; Chuah C; Kaeda J; Goldman JM; Apperley JF; Marin D
    Br J Haematol; 2007 Jun; 137(5):423-8. PubMed ID: 17428238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
    Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
    Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.